Lilly Endowment Inc, an insider of Eli Lilly and Co (LLY), executed a significant sale of 92,611,157 shares on November 19, 2025. The shares were sold at a price of $1,053.52 each, resulting in a total transaction value of $97.57 billion. Following this transaction, Lilly Endowment Inc retains 92,611,157 shares of the company.
Eli Lilly & Co, headquartered in Indianapolis, Indiana, is a leading player in the pharmaceuticals sector, employing approximately 47,000 individuals. The company is engaged in the discovery, development, manufacture, and sale of a diverse range of pharmaceutical products. Its portfolio includes cardiometabolic health products such as Basaglar, Humalog, and Jardiance, alongside oncology and immunology products like Cyramza and Taltz. Additionally, Eli Lilly is involved in radiopharmaceutical development through its subsidiary, POINT Biopharma Global Inc.
The market capitalisation of Eli Lilly stands at $992.3 billion, with a price-to-earnings ratio of 53.89 and earnings per share of 20.45. The company also offers a dividend yield of 57.2%. Upcoming earnings reports are anticipated, with estimates of $8.09 per share and $18.7 billion in revenue for August 5, 2026, and $7.53 per share with $17.5 billion in revenue for April 29, 2026.
Insider transactions, such as this sale, must be reported to the SEC, providing transparency regarding the actions of company executives. While the reasons for such sales can vary—from diversification to personal financial needs—investors are advised to consider broader patterns of insider activity rather than isolated transactions when assessing market signals.